US EditionPublished • loading... • Updated
Pfizer faces challenging years on fading COVID sales, ...
- On Tuesday, Pfizer forecast modest 2026 guidance with revenue of $59.5 billion to $62.5 billion and adjusted profit $2.80–$3 per share, while shares were largely flat in premarket trading.
- Amid waning Covid demand, Pfizer cited falling vaccine and Paxlovid sales and pricing concessions from a drug-pricing deal with the Trump administration that compressed margins.
- The company expects a $1.5 billion drop from lower Covid sales and another $1.5 billion from lost exclusivity, with $17 billion potentially affected by patent and regulatory exclusivity expirations in 2026 and 2028.
- Executives will prioritise development spending over buybacks, the company said, exceeding 2025 cost‑saving goals and targeting more than $7 billion in cuts by 2027, mostly by next year.
- In recent years Pfizer has pursued big acquisitions to build future revenue streams, including last month's $10 billion Metsera buy and the $43 billion Seagen tie-up in 2023; Chief Executive Albert Bourla said, `Vaccines are an essential part of any health care system`.
Insights by Ground AI
36 Articles
36 Articles
Its turnover should be affected, among other things, by the reflux of the VOCID-19. The post Pfizer forecasts a turnover of 2026 dug appeared first on Les Affaires.
Coverage Details
Total News Sources36
Leaning Left3Leaning Right3Center7Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 23%
C 54%
R 23%
Factuality
To view factuality data please Upgrade to Premium
